What changed
$PODD — BUY 📊
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
🎯 Q1 FY26 | Rev $1B | EPS $1.42 vs $1.19 🟢
💡 Consensus expected 25-27% constant-currency revenue growth and EPS of $1.19; actual results delivered 33% growth (constant currency) and $1.42 EPS, a 19% beat. Market forward estimates appear to lag the current run-rate, implying a valuation that does not fully reflect the trajectory.
📉 Reward/Risk: 3.9:1
🏢 Business Quality: 8/10 - Tubeless insulin pump leader with high recurring revenue, strong brand moat, and expanding global TAM; durable competitive advantage and pricing power.
📊 Valuation: cheap on forward P/E (25.3x annualized Q1 vs historical trailing 35.4x), fair on trailing P/E.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/PODD0617
Also in play: $TNDM $DXCM $ABT $MDT $EW $ROG
Why it matters
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.